×

Karyopharm Announces Five Clinical Data Presentations at ASCO 2014

Karyopharm Therapeutics Logo

NATICK, Mass., April 22, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced that clinical and preclinical data for its lead drug candidate, Selinexor (KPT-330), a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from May 30 to June 3, 2014 in Chicago, Illinois. Clinical results to be presented include updated data from Karyopharm's Phase 1 studies in patients with advanced hematologic malignancies, solid tumors and sarcomas. Karyopharm will host an investor and analyst briefing Monday, June 2, 2014 in Chicago, Illinois at 6:30 p.m. CT.

Oral Presentation:
Saturday, May 31, 2014, 1:15 – 1:27 p.m. CT
Title: A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients with heavily pretreated non-Hodgkin lymphoma (NHL). (Abstract #8518)
Presenter: Martin Gutierrez, MD
Location: E Arie Crown Theater
Poster Presentations:
Friday, May 30, 2014, 1:00 – 4:00 p.m. CT (poster highlights presentation)
Title: A first-in-class, first-in-human phase 1 trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients with advanced solid tumors. (Abstract #2537)
Presenter: Morten Mau-Soerensen, MD, PhD
Poster Display: E354b, Poster Board #52
Discussion: 4:30-5:45p.m. CT, E Arie Crown Theater
Saturday, May 31, 2014, 1:15 – 4:15 p.m. CT (poster highlights presentation)
Title: A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients with relapsed/refractory acute myeloid leukemia (AML). (Abstract #7032)
Presenter: Karen W. L. Yee, MD
Poster Display: S405, Poster Board #24
Discussion: 4:45-6:00p.m. CT, S406
Monday, June 2, 2014, 8:00 – 11:45 a.m. CT (poster presentation)
Title: A phase 1b food effect study of the first-in-class, oral, selective inhibitor of nuclear export (SINE) selinexor (KPT-330) in patients with advanced sarcomas. (Abstract #10587)
Presenter: Mrinal M. Gounder, MD
Poster Display: E354b, Poster Board #294
Monday, June 2, 2014, 8:00 – 11:00 a.m. CT (poster highlights presentation)
Title: Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist KPT-330 (Selinexor) in patients with platinum resistant/refractory ovarian cancer (OvCa). (Abstract #5522)
Presenter: John Martignetti, MD, PhD
Poster Display: E354b, Poster Board #11
Discussion: 11:30-12:45 p.m. CT, Room E354a

About Selinexor

Selinexor (KPT-330) is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. Selinexor functions by binding with the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus, which subsequently reinitiates and amplifies their tumor suppressor function. This is believed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. To date, approximately 300 patients have been treated with Selinexor in Phase 1 and 2 trials in advanced hematologic malignancies and solid tumors. Additional Phase 1 and Phase 2 studies are ongoing or currently planned and three registration-directed clinical trials in hematological indications are expected to begin enrollment during 2014. The latest clinical trial information for Selinexor is available at www.clinicaltrials.gov.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. SINE compounds have shown biological activity in models of cancer, autoimmune disease, certain viruses, and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Natick, Massachusetts.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the therapeutic potential of and potential clinical development plans for Karyopharm's drug candidates, including the timing of initiation of certain trials and of the reporting of data from such trials. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any of Karyopharm's SINE compounds, including Selinexor (KPT-330), or any other drug candidate that Karyopharm is developing will successfully complete necessary preclinical and clinical development phases or that development of any of Karyopharm's drug candidates will continue. Further, there can be no guarantee that any positive developments in Karyopharm's drug candidate portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: Karyopharm's results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Karyopharm's ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash requirements and expenditures; development of drug candidates by Karyopharm's competitors for diseases in which Karyopharm is currently developing its drug candidates; and Karyopharm's ability to obtain, maintain and enforce patent and other intellectual property protection for any drug candidates it is developing. These and other risks are described under the caption "Risk Factors" in Karyopharm's Annual Report on Form 10-K for the year ended December 31, 2013, which is on file with the Securities and Exchange Commission (SEC), and in other filings that Karyopharm may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Paul Brannelly paul@karyopharm.com 508-975-4820 Jennifer McNealey jmcnealey@annesassociates.com 917-392-3400

Source:Karyopharm Therapeutics